178
Participants
Start Date
February 15, 2021
Primary Completion Date
June 16, 2022
Study Completion Date
August 31, 2023
Tislelizumab
200 mg administered intravenously once every 3 weeks on day 1 of each cycle
Ociperlimab
900 mg administered intravenously once every 3 weeks on day 1 of each cycle
Acibadem city clinic tokuda umhat ead, department of medical oncology, Sofia
National Cancer Institute, Kiev
"Mhat uni hospital ood", Panagyurishte
Complex Oncology Center Rousse Eood, Rousse
Phramongkutklao Hospital, Ratchathewi
Siriraj Hospital, Bangkok Noi
Medical center nadezhda clinical eood, Sofia
"Medical and diagnostic center of private enterprise private production company acinus", Kirovograd
Medical center of llc oncolife, Kropyvnytskyi
Srinagarind Hospital (Khon Kaen University), Khon Kaen
Communal Non-Profit Enterprise Of Sumy Regional Council Sumy Regional Clinical Oncological Dispensar, Sumy
Keimyung University Dongsan Medical Center, Daegu
Liaoning Cancer Hospital & Institute - Medical Oncology - Oncology, Shenyang
Jilin Guowen Hospital, Jilin
Oncological Scientific Center LLC, Pesochny
Xuzhou Cancer Hospital, Xuzhou
Anhui Provincial Cancer Hospital, Hefei
Qilu Hospital of Shandong University, Jinan
Linyi Cancer Hospital, Shandong
Tianjin Medical University Cancer institute & Hospital, Tianjin
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang
State healthcare institution oncologic dispensary no. 2 - health department of krasnodar region, Krasnodar
The First Affiliated Hospital of Xiamen University - Oncology, Xiamen
Chongqing Cancer Hospital, Chongqing
Hubei Cancer Hospital - Oncology, Wuhan
Southwest Hospital, Chongqing
Hunan Cancer Hospital - GCP Office, Changsha
"Fsbi of higher educationogarev mordovia state university", Saransk
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Henan Cancer Hospital - Oncology, Zhengzhou
State budgetary healthcare institution-chelyabinsk regional clinical center of oncology and nuclear, Chelyabinsk
Sun yat-sen memorial hospital, sun yat-sen university (south), Guanzhou
The Tumor Hospital Affiliated to Guangxi Medical University, Nanning
Hainan Cancer Hospital, Haikou
The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an
Gansu Provincial Hospital, Lanzhou
General Hospital of Ningxia Medical University, Yinchuan
Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi
Obstetrics and Gynecology Hospital of Fudan University, Shanghai
Beijing Cancer Hosptial, Beijing
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
Szpitale Pomorskie Spółka z ograniczoną odpowiedzialnością, Gdynia
"Sbhi of stavropol region pyatigorsk interdistrict oncologic dispensary", Pyatigorsk
Arkhangelsk regional clinical oncological dispensary, Arkhangelsk
Kyemyung University Dongsan Hospital, Daegu
Ajou University Hospital, Gyeonggi-do
National Cancer Center, Gyeonggi-do
Seoul National University Bundang Hospital, Gyeonggi-do
Asan Medical Center, Seoul
Gangnam Severance Hospital, Seoul
Korea Institute of Radiological & Medical Sciences, Seoul
Korea University Guro Hospital, Seoul
Samsung Medical Center, Seoul
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University Health System, Seoul
Chi Mei Hospital, Liouying, Tainan City
Linkou Chang Gung Memorial Hospital, Tainan City
National Cheng Kung University Hospital, Tainan City
Mackay Memorial Hospital, Taipei
National Taiwan University Hospital, Taipei
Taipei Veterans General Hospital, Taipei
Songklanagarind Hospital, Prince of Songkla University, Hat Yai
Second Hospital Of Shanxi Medical University, Taiyuan
Przychodnia lekarska komed, Konin
"Public Non-Profit Institution Precarpathian Oncology Center Of Ivano-Frankivsk Regional Council", Ivano-Frankivsk Oblast
Volyn Regional Medical Center Of Oncology, Lutsk
Lead Sponsor
BeiGene
INDUSTRY